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Introduction
Age-related macular degeneration (AMD) is the leading
cause of legal blindness in Caucasians over 50 years of
age in the United States, with choroidal neo-
vascularization (CNV) accounting for the majority
of cases.1–3 A population-based study estimated that
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Background: To evaluate the safety and efficacy of verteporfin photodynamic therapy (PDT) in patients with subfoveal
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their baseline examinations. The secondary efficacy outcome was the changes in the logarithm of the minimum
angle of resolution visual acuities at 1-year follow-up. Complications were monitored and tabulated.
Results: Forty-eight eyes of 48 patients with subfoveal CNV secondary to AMD were enrolled in this study. The mean
follow-up was 12.56 ± 1.37 months. At their last visit, 10.4% of eyes had more than 1 line improvement in Snellen
visual acuity, 72.9% of eyes had no change, and 16.7% experienced more than 1 line of visual acuity loss (7 eyes
lost < 3 lines of Snellen visual acuity, 1 eye lost between 3 and 6 lines). None experienced more than 6 lines
of visual loss. There was no statistically significant difference between baseline and final visual acuity for eyes
with predominantly classic CNV, minimally classic CNV and occult without classic CNV (Wilcoxon Signed Rank test,
p = 0.59 ). There was a positive correlation between baseline visual acuity and final visual outcome (Kruskal-Wallis
test, p = 0.002). No severe systemic and ocular adverse events were encountered.
Conclusion: Of our patients with subfoveal CNV secondary to AMD, 83.3% could maintain or improve their visual
acuity 1 year after verteporfin PDT. The risk of deterioration in visual acuity due to subfoveal CNV could be reduced
by verteporfin PDT. Baseline visual acuity is significantly correlated with the final proportion of visual outcome.
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3.7% of the population over 75 years of age and 14.4%
of the population over 90 years are visually impaired
due to AMD, with 34% of patients being identified
with neovascular AMD.4 In Taiwan, a population-
based survey of ocular diseases in residents aged over
50 years disclosed that the prevalence of AMD was
14.3% among this population with visual impairment
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(defined as best-corrected visual acuity in the better
eye < 6/18).5 A retrospective study by Chen and
associates6 revealed that only 10.5% of patients suffering
from submacular hemorrhage secondary to AMD
demonstrated an improvement in visual acuity 6 months
after the initial presentation. Their final mean visual
acuity was 0.069. Photodynamic therapy with
verteporfin was designed to selectively occlude the
CNV without damage to the overlying retina. The
Treatment of Age-related Macular Degeneration With
Photodynamic Therapy (TAP) study has shown the
benefit of photodynamic therapy (PDT) with
verteporfin for predominantly classic subfoveal CNV
secondary to AMD,7,8 as well as for patients complicated
with occult without classic CNV and minimally classic
CNV.9–11 This retrospective study was conducted to
evaluate the visual outcome and fluorescein angio-
graphic changes after verteporfin PDT for patients
with subfoveal CNV caused by AMD in Taiwan.
Methods
Patient selection
We retrospectively reviewed the chart records and
fluorescein angiography (FAG) of patients who were
treated with verteporfin PDT between September
2001 and March 2003, and who had completed at
least 1 year of follow-up at Taipei Veterans General
Hospital. Forty-eight eyes of 48 patients with subfoveal
CNV secondary to AMD were enrolled. Patients were
included based on their initial FAG.
CNV subtypes were classified as predominantly
classic CNV, minimally classic CNV, and occult without
classic CNV. Classic and occult CNV were based on
the definitions from the Macular Photocoagulation
Study (MPS) Group.12 Predominantly classic CNV
was defined as a lesion in which the classic CNV
component accounted for more than 50% of the entire
baseline lesion. If less than 50%, the lesion was graded
as minimally classic CNV. For all CNV, the greatest
linear dimension (GLD), including the CNV, area of
leakage and areas of blocked fluorescence in the lesion,
was less than 5,400 μm.
Verteporfin PDT and follow-up assessment
Verteporfin PDT was administered according to the
TAP study protocol. Follow-up visits were scheduled
at 3-monthly intervals; measurement of best-corrected
visual acuity, biomicroscopic examination and FAG
were performed. Increased subretinal hemorrhage,
serous detachment and lipid exudates on fundus
examination were considered disease progression.
Retreatment was considered at 3-monthly intervals if
there was fluorescein leakage from the CNV and if no
serious adverse events had resulted from prior
treatment. Patients’ demographic data retrieved
from chart records were age, gender, Snellen visual
acuity, treatment spot size, GLD, and fundus
characteristics (hemorrhage, fibrosis, pigment epithelial
detachment).
Outcome measurements
Patients’ Snellen visual acuity was transformed to
logarithm of the minimum angle of resolution
(logMAR) units for statistical assessment.13 For ease
of analysis, visual acuity that was worse than Snellen
visual acuity 1/60 was designated as 6/720
(logMAR = 2.1). The primary efficacy outcomes were
the proportions of patients whose Snellen visual acuities
had more than 1 line increase, no change or more than
1 line decrease 1 year after study entry compared with
their baseline examinations. The secondary efficacy
outcome was the changes in logMAR visual acuities at
1-year follow-up. Final angiographic outcomes
(complete absence of leakage, leakage within the
original area, progression compared with original
lesion) were also recorded. The occurrence of severe
adverse events (bleeding gastric ulcer, elevated blood
pressure, suprachoroidal hemorrhage) and ocular
adverse effects were recorded.
Statistical analysis
Patients’ demographic data were summarized by
descriptive statistics using SPSS version 11, Professional
Statistics Release (SPSS Inc, Chicago, IL, USA).
Correlations between the final proportion of visual
acuity change, baseline visual acuity, CNV subtypes,
GLD, and fundus characteristics were analyzed using
the Wilcoxon Signed Rank test and Kruskal-Wallis test.
All p values were the results of 2-tailed tests and the level
of statistical significance was set at p less than 0.05.
Results
Forty-eight eyes of 48 patients were enrolled in this
study. Eleven eyes were classified as predominantly
classic CNV, four eyes were minimally classic CNV,
and 33 eyes were occult without classic CNV. Dem-
ographic data are shown in Table 1. There were no
statistically significant differences in age, follow-up
profiles, retreatment or lesion size among the 3 groups.
The mean initial logMAR visual acuities of eyes
with predominantly classic CNV, minimally classic
CNV and occult with no classic CNV were 1.78 ± 0.37,
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1.25 ± 0.78 and 1.24 ± 0.65, respectively (Table 2).
The mean initial logMAR visual acuity for all patients
was 1.35 ± 0.64. The initial visual acuities of the 3
groups of eyes were not statistically significantly
different (Kruskal-Wallis test, p = 0.09). The mean
follow-up was 12.56 ± 1.37 months.
Visual outcomes
The final mean logMAR visual acuities of eyes with
predominantly classic CNV, minimally classic CNV
and occult with no classic CNV were 1.70 ± 0.45,
1.24 ± 0.71, and 1.20 ± 0.50 (Kruskal-Wallis test, p =
0.10). The final mean logMAR visual acuity for all eyes
was 1.31 ± 0.54 (Table 2). There were no significant
differences between baseline and final visual acuities
in eyes with predominantly classic CNV, minimally
classic CNV and occult without classic CNV (Wilcoxon
Signed Rank test, p = 0.59). At their last visit, 10.4%
of eyes showed improvement in Snellen visual acuity,
72.9% remained stable (35/48; 9 eyes with
predominantly classic CNV, 3 eyes with minimally
classic CNV, 23 eyes with occult without classic CNV),
and 16.7% had a decrease of more than 1 line. Only 1
patient (2%) lost more than 3 lines of Snellen visual
acuity. No eye lost more than 6 lines in this series
(Table 3).
Table 1. Demographic data
PC (n = 11) MC (n = 4) Occult (n = 33) p*
Age (yr) 70.8 75.0 75.5 0.41
Follow-up (mo) 13.12 12.06 12.51 0.73
Retreatment 2.63 2.0 2.56 0.33
Lesion size (μm) 4,014.12 4,760.75 3,549.15 0.31
*Kruskal-Wallis test. MC = minimally classic choroidal neovascularization (CNV); Occult = occult without classic CNV; PC = predominantly classic CNV.
Table 2. Visual acuity data
PC MC Occult
Baseline Snellen VA 6/20–CF/20 cm 6/12–CF/20 cm 6/12–CF/20 cm
Baseline logMAR
Mean ± SD 1.78 ± 0.37 1.25 ± 0.78 1.24 ± 0.65
Median 1.69 1.24 1.24
Final logMAR
Mean ± SD 1.70 ± 0.45 1.24 ± 0.71 1.20 ± 0.51
Median 1.54 1.43 1.30
CF = counting fingers; logMAR= logarithm of the minimum angle of resolution; MC = minimally classic choroidal neovascularization (CNV);
Occult = occult without classic CNV; PC = predominantly classic CNV; SD = standard deviation; VA = visual acuity.
Table 3. Proportion of visual acuity change* after verteporfin photodynamic therapy
PC MC Occult All eyes
Increase
> 1 line 0 1 4 5 (10.4%)
1–3 lines 0 1 4 5 (10.4%)
> 3 lines 0 0 0 0 (0%)
No change 9 3 23 35 (72.9%)
Decrease
> 1 line 2 0 6 8 (16.7%)
1–3 lines 2 0 5 7 (14.7%)
> 3 lines 0 0 1 1 (2.0%)
> 6 lines 0 0 0 0 (0%)
*Tested with Snellen visual chart. MC = minimally classic choroidal neovascularization (CNV); Occult = occult without classic CNV; PC = predominantly
classic CNV.
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The final proportion of visual acuity change was
not correlated with fluorescein angiogram subtypes
(Kruskal-Wallis test, p = 0.10) or GLD (Kruskal-Wallis
test, p = 0.40). There was a positive correlation between
baseline and final visual acuity (increase > 1 line, no
change, decrease > 1 line) for all patients (Kruskal-
Wallis test, p = 0.002). FAG showed complete absence
of fluorescein leakage in 32% of eyes, leakage within
the original CNV in 44% of eyes, and progression
compared with the original lesion in 24% of eyes
within 1 year. The mean number of retreatments was
2.40 ± 0.8.
Submacular hemorrhage was found in 24 eyes at
the baseline examination and the incidence was not
significantly different among eyes with predominantly
classic, minimally classic and occult without classic
CNV. Intravitreal injection of tissue plasminogen
activator (tPA) plus sulfur hexafluoride (SF6) was
performed in 1 eye to clearly identify the CNV. The
presence of submacular hemorrhage was not correlated
with final change in visual acuity (Kruskal-Wallis test,
p = 0.57) and final logMAR visual acuity (Kruskal-
Wallis test, p = 0.80). Increased subretinal hemorrhage
after treatment was noted in 7 eyes (14.6%): 6 eyes
after the first course of treatment; and the last eye after
the second course of treatment.
Safety and complications
No severe adverse events (bleeding gastric ulcer,
elevated blood pressure, suprachoroidal hemorrhage)
were noted during treatment and follow-up. Two
patients complained of injection-related back pain,
which resolved soon after injection. No verteporfin-
related acute vision loss (defined as a decrease of at
least 4 lines of visual acuity within 7 days of treatment)
was noted (Table 4).
Discussion
AMD is a severe public health problem that can be
complicated with subfoveal CNV leading to severe,
irreversible central vision loss.1–4,14 Patients with pre-
dominantly classic CNV may have a 60% chance of
developing a 3-line loss of Snellen visual acuity in 1
year.7 Unfortunately, use of traditional laser photo-
coagulation is limited to a subset of patients with jux-
tafoveal or extrafoveal lesions. This benefit, however,
comes at the cost of indiscriminate destruction of the
overlying retina at the risk of immediate and irreversible
loss of vision at the site of laser light application.12,15,16
Verteporfin PDT was designed to selectively occlude
the CNV without damage to the overlying retina.17
The TAP studies concluded that verteporfin PDT
could sustain visual acuity, stabilize contrast sensitivity,
and preserve quality of vision in eyes with predominantly
classic CNV.7,8,10,11 This favorable benefit for eyes with
occult without classic CNV and minimally classic
CNV was also disclosed in the Verteporfin In
Photodynamic therapy (VIP) report9 and Verteporfin
In Minimally classic CNV (VIM) trial.18
Our study disclosed that 10.4% of eyes (1 with
minimally classic and 4 with occult without classic
CNV) could have improvement in Snellen visual acuity.
Among eyes complicated with subfoveal CNV treated
with verteporfin PDT, 72.9% (35/48; 9 eyes with
predominantly classic CNV, 3 eyes with minimally
classic CNV, 23 eyes with occult without classic CNV)
could maintain their Snellen visual acuity with no
change for 1 year. The treatment benefit (maintenance
or improvement in Snellen visual acuity) for eyes with
predominantly classic, minimally classic and occult
with no classic CNV were 81.8% (9/11), 75% (3/4)
and 69.7% (23/33), respectively. The estimated 1-
year visual loss of less than 3 lines after verteporfin
PDT in this study was 98%. The TAP study disclosed
that 48% of eyes could maintain or improve their
Snellen visual acuity, and the estimated visual loss of
less than 3 lines was 71%.7 In the VIP study, 23.1% of
eyes could maintain or improve their Snellen visual
acuity, and the estimated incidence of visual loss of less
than 3 lines was 45% (Table 3).7–11 In comparison with
these carefully designed TAP and VIP studies, our
study has some points that need to be addressed.
Table 4. Side effects and complications
All patients (n = 48) VIP TAP
Verteporfin-related acute visual acuity loss (%) 0 4.4 0.7
Injection site adverse reaction (%) 0 6.7 14.4
Infusion-related back pain (%) 4.2 (2/48) 2.2 2.5
Allergic reactions (%) 0 0 0
Photosensitivity reactions (%) 0 0.4 3.0
TAP = treatment of age-related macular degeneration with photodynamic therapy study; VIP = verteporfin in photodynamic therapy report.
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First, our series included patients complicated with
predominantly classic CNV, minimally classic CNV or
occult without classic CNV, which is different from
the TAP (reported on predominantly classic lesions)
and VIP (reported on fully occult lesions) studies.7–11
Second, the baseline visual acuity in our series (logMAR,
1.35; approximate Snellen equivalent, 3/60) was much
worse than that in the TAP study (mean, 20/80;
range, 20/40 to 20/200).7,8 It was also worse than the
median visual score in the Japanese Age-related Macular
Degeneration Trial (JAT).19 That could be the reason
for the much larger proportion of estimated 1-year
visual loss of less than 3 lines in our series. Third, our
series was a non-randomized study, in contrast with
the randomized, double-masked, multicenter TAP
and VIP studies.
Our study also disclosed that baseline visual acuity
was positively correlated with the final visual acuity
change 1 year after study entry. However, the TAP
studies did not show that the baseline visual acuity of
eyes with predominantly classic CNV influenced
outcomes. Axer-Siegel and associates reported that
the better visual outcome in eyes that presented with
better visual acuity was probably due to the poor
natural history of predominantly classic CNV.20–23
This result may reflect the benefit of early therapeutic
intervention.20 For patients with occult without
classic CNV, the VIP trial showed more benefit
from treatment in patients with either smaller lesions
(< 4 MPS disc diameter) or lower levels of visual
acuity (Snellen equivalent worse than 20/50).9 That
could explain why patients with occult without classic
CNV might have a lower mean baseline logMAR
visual acuity of 1.24 (Snellen equivalent < 20/200),
and a smaller mean lesion size of 3,549.15 μm (< 4
MPS disc diameter).
There was no statistically significant difference
in the init ial  logMAR visual acuity among
predominantly classic, minimally classic and occult
without classic CNV. Previous studies disclosed that
the different natural histories of predominantly classic
CNV and occult without classic CNV could result in
different changes in visual acuity.20–23 Patients
complicated with predominantly classic CNV usually
suffer from a severe and rapid central vision loss in
contrast with the slowly deteriorating visual acuity in
patients complicated with occult CNV. However,
our series could not make such a conclusion, perhaps
due to the unequal sample distribution (predomi-
nantly classic, 11; minimally classic, 4; occult with-
out classic, 34) and patient selection. A large sample
size and randomized study are mandatory for fur-
ther evaluation.
Baseline examination found submacular hem-
orrhage in 24 eyes before treatment, which was not
correlated to final visual acuity. However, increased
hemorrhage was noted after PDT in 7 eyes, causing
rapid decline in visual acuity. While visual deterioration
and hemorrhage are part of the natural history of
CNV-related conditions, the latter usually occurs 2–3
months after initiation of therapy instead of acutely
within 1 week. This massive submacular hemorrhage
could result in a median 8.5 lines decrease compared
with pretreatment acuity.24 The TAP and VIP studies
reported that increased hemorrhage after verteporfin
PDT occurred mostly in eyes with occult without
classic CNV.7–11 In our series, it occurred in 7 eyes after
verteporfin PDT, 2 eyes had predominantly classic
CNV and the other 5 eyes had occult with no classic
CNV. Intravitreal injection of tPA and SF6 was
performed in 2 eyes. After the hemorrhage was
displaced, 1 eye received 1 verteporfin PDT retreatment
3 months after the first treatment, and the other eye
received 1 session of transpupillary thermotherapy
(TTT) 3 months later. Baseline Snellen visual acuity
was 6/60 for the first patient and 2/60 for the second
patient. Final Snellen visual acuity was 3/60 for the
first patient and 4/60 for the second patient. Flat
retinal scar without fluorescein leakage was noted in
their final visits. The submacular hemorrhage was not
severe enough to interfere with verteporfin therapy in
the other 5 eyes. There was no statistical difference
between baseline and final logMAR visual acuity in
these 7 eyes (Kruskal-Wallis test, p = 0.25).
No severe adverse events were noted in our study
except for injection-related back pain, and there was
no acute severe vision loss after treatment. This
showed that verteporfin PDT was tolerated well in
Chinese patients with AMD complicated with
subfoveal CNV.
Conclusion
Our study disclosed that 83.3% of patients with
subfoveal CNV secondary to AMD could maintain or
improve their visual acuity 1 year after verteporfin
PDT to reduce the risk of visual deterioration. Baseline
visual acuity was correlated with the final proportion
of visual acuity change. A large population-based
study is necessary to explore if there are any racial
differences in the natural course of the disease and the
poor initial visual acuity. Early detection of the disease
and proper management to reduce the risk of central
vision loss are mandatory for the treatment of patients
with AMD complicated with subfoveal CNV.
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